血必净联合乌司他丁治疗ICU脓毒症患者的效果分析

Analysis of the Effect of Xuebijing Combined with Ulinastatin on ICU Sepsis Patients

目的分析血必净联合乌司他丁治疗ICU脓毒症患者的临床效果。方法该次研究对象为方便选取该院2013年1月-2019年5月收治的96例ICU脓毒症患者,将其随机分为两组,分别为研究组和对照组,每组48例,给予对照组患者单纯乌司他丁治疗,研究组患者在对照组基础上增加血必净治疗,两组患者均采取静脉滴注,12 h/次,每7天为1疗程。对比两组患者的治疗后的各项指标、住院时间、28 d存活率、机械通气时间。结果治疗后,研究组患者的LPS为(22.87±9.12)EU/mL明显优于对照组患者的LPS为(32.34±7.26)EU/mL(t=5.630,P=0.000);究组患者的TNF-ɑ为(22.08±8.82)pg/mL明显优于对照组患者的TNF-ɑ(29.26±6.41)pg/mL(t=4.560,P=0.000);研究组患者的IL-6为(205.09±54.31)pg/mL明显优于对照组患者的IL-6 (283.11±68.28)pg/mL (t=6.200,P=0.000);研究组患者的PCT为(0.82±0.35)ng/mL明显优于对照组患者的PCT(1.68±0.91)ng/mL(t=6.110,P=0.000),差异有统计学意义(P<0.05);治疗后,研究组患者在机械通气时间为(10.82±3.35)d明显比对照组患者的机械通气时间(16.62±3.91)d短(t=7.800,P=0.000);研究组ICU的住院时间为(12.83±4.18)d明显比对照组患者的ICU住院时间(17.36±4.29)d短(t=5.240,P=0.000);研究组患者28 d的存活率为83.25%明显高于对照组患者28 d的存活率70.83%,差异有统计学意义(χ~2=435.34,P=0.000)。结论对ICU脓毒症患者采取血必净联合乌司他丁治疗的临床疗效显著,能有效改善患者的临床症状,缩短患者的住院时间,提高患者的存活率,缩短机械通气时间,提高患者满意程度。

Objective To analyze the clinical effect of Xuebijing combined with ulinastatin in the treatment of ICU sepsis patients. Methods Convenient select this study was conducted on 96 patients with ICU sepsis treated in the hospital from January 2013 to May 2019. They were randomly divided into two groups, the study group and the control group, with 48 people in each group. The patients in the control group were treated with ulinastatin alone. The patients in the study group were treated with Xuebijing on the basis of the control group. The patients in both groups were treated with intravenous infusion for 12 hours at a time and every 7 days was a course of treatment. After treatment, the indexes, hospital stay, 28 day survival rate, and mechanical ventilation time were compared between the two groups of patients. Results After treatment, the LPS in the study group was(22.87±9.12) EU/mL, which was significantly better than that in the control group(32.34±7.26) EU/mL(t= 5.630, P=0.000);TNF-ɑ was(22.08±8.82)pg/mL, significantly better than TNF-ɑ in the control group(29.26±6.41) pg/mL(t=4.560, P=0.000);IL-6 in the study group was(205.09±54.31) pg/mL was significantly better than IL-6 in the control group(283.11±68.28)pg/mL(t=6.200, P=0.000);PCT in the study group was(0.82±0.35)ng/mL significantly better than the control group PCT(1.68 ±0.91)ng/mL(t =6.110,P =0.000), the differences were statistically significant(P<0.05);after treatment, the mechanical ventilation time of patients in the study group was(10.82 ±3.35) d significantly higher than the control group of mechanical ventilation time of the patients was(16.62±3.91)d(t=7.800, P=0.00);the ICU stay in the study group was(12.83±4.18)d, which was significantly longer than the ICU stay in the control group(17.36±1.29) d, shorter(t=5.240, P= 0.00);the 28 d survival rate of patients in the study group was 83.25%, which was significantly higher than the 28 d survival rate of patients in the control group, 70.83%,the differences were statistically significant (χ~2=435.340, P= 0.000). Conclusion The clinical efficacy of Xuebijing combined with ulinastatin in ICU sepsis patients is significant, which can effectively improve the clinical symptoms of patients, shorten the length of hospital stay,increase the survival rate of patients, shorten the time of mechanical ventilation, and improve patients’ satisfaction degree.